Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1182/blood-2012-11-467787 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sequential occurrence of BCR::ABL1-negative MPN and CML and vice versa: results from a real world cohort.
Int J Hematol
September 2025
MLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, 81377, Munich, Germany.
Chronic myeloid leukemia (CML) and BCR::ABL1-negative MPN were thought to be mutually exclusive, but synchronous and sequential cases have been reported. We screened 35,001 patients for BCR::ABL1 fusion or JAK2, CALR, or MPL mutations to investigate the sequential development of CML and BCR::ABL1 negative-MPNs. We discovered that 5.
View Article and Find Full Text PDFBCR::ABL1-Positive Secondary B-Acute Lymphoblastic Leukemia Mimicking Acute Megakaryoblastic Leukemia Following Multiple Myeloma.
Turk J Haematol
August 2025
Affiliated Hospital of Xuzhou Medical University, Department of Hematology, Xuzhou, China.
Olverembatinib (HQP1351)-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia in blast phase: results from a real-world study.
Front Immunol
May 2025
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Background: Relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (R/R Ph ALL) and chronic myeloid leukemia in the blast phase (CML-BP) are associated with poor prognoses. Olverembatinib (HQP1351), a novel third-generation tyrosine kinase inhibitor (TKI), has shown promising efficacy and safety in clinical trials against nearly all BCR-ABL1 kinase mutations, including .
Methods: Data were collected and analyzed to evaluate the efficacy and safety of olverembatinib-based therapy for advanced Ph leukemia.
[The Factors Related to Treatment Failure in Children with Acute Lymphoblastic leukemia--Analysis of Multi-Center Data from Real World in Fujian Province].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
December 2024
Department of Pediatric Hematology, Fujian Medical University Union Hospital, Fujian Institute of Hematology, Fujian Provincial Key Laboratory, Fuzhou 350001, Fujian Province, China.
Objective: To analyze the related factors of treatment failure in children with acute lymphoblastic leukemia (ALL) in real-world.
Methods: The clinical data of 1414 newly diagnosed children with ALL admitted to five hospital in Fujian province from April 2011 to December 2020 were retrospectively analyzed. Treatment failure was defined as relapse, non-relapse death, and secondary tumor.
Fungal secondary metabolites as a potential inhibitor of T315I- BCR::ABL1 mutant in chronic myeloid leukemia by molecular docking, molecular dynamics simulation and binding free energy exploration approaches.
J Genet Eng Biotechnol
December 2024
Hematologic Disease Center, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang Medical University, Urumqi 830011, China. Electronic address:
Background: Chronic Myeloid Leukemia (CML) is particularly challenging to treat due to the T315I BCR::ABL1 mutation. Although fungal metabolites are known for their pharmaceutical potential, none are approved for CML. Our study screened approximately 2000 fungal secondary metabolites to discover inhibitors targeting the T315I- BCR::ABL1 mutant protein.
View Article and Find Full Text PDF